Related Experiment Video
Updated: May 15, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in experimental tumor
Wenjia Lou1, Qing Chen, Leina Ma
1Lab. of Biotherapy of Cancer, Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China.
Abstract:
It has been demonstrated that numerous microRNAs (miRNAs) have potent tumor-suppressing effects on a variety of cancers, implicating a possible application of miRNA in tumor therapy. Oncolytic adenovirus is a suitable vector to deliver tumor suppressor genes for treatment of cancers. However, it remains unknown whether co-expression of tumor suppressor genes and miRNAs can contribute to a more potent antitumor capacity within an oncolytic adenovirus delivery system. In this study, we found that expression of miRNA-34a was reduced in hepatocellular carcinoma (HCC), and the reduced expression of miRNA-34a was associated with worse outcome of HCC patients. Thus, we developed an oncolytic adenoviral vector, AdCN205, to co-express miRNA-34a and IL-24 driven by an adenovirus endogenous E3 promoter in HCC cells. High levels of miRNA-34a and IL-24 expression were detected in AdCN205-IL-24-miR-34a-infected HCC cells. AdCN205-IL-24-miR-34a significantly induced dramatic antitumor activity, as compared with that induced by AdCN205-IL-24 or AdCN205-miR-34a alone. Transfer of miRNA-34a into HCC cells inhibited the expression of its target genes, Bcl-2 and SIRT1. Treatment of established xenograft HCC tumors with AdCN205-IL-24-miR-34a in a mouse model resulted in complete tumor regression without recurrence. Taken together, our data provide a promising and reasonable delivery strategy of double-aimed cancer therapy, in which miRNAs and tumor-suppressing genes are used simultaneously.
Insights
This study developed an oncolytic adenovirus to co-express miRNA-34a and IL-24, showing potent antitumor effects against hepatocellular carcinoma (HCC). This dual-gene therapy led to complete tumor regression in mice, offering a promising cancer treatment strategy.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- MicroRNAs (miRNAs) exhibit tumor-suppressing properties, suggesting therapeutic potential in cancer treatment.
- Oncolytic adenoviruses are effective vectors for delivering tumor suppressor genes.
- The combined efficacy of co-expressing tumor suppressor genes and miRNAs via oncolytic adenoviruses remains largely unexplored.
Purpose of the Study:
- To investigate the potential of co-expressing miRNA-34a and IL-24 using an oncolytic adenovirus for hepatocellular carcinoma (HCC) therapy.
- To evaluate the antitumor capacity of this combined gene therapy in HCC cells and a mouse model.
Main Methods:
- Developed an oncolytic adenoviral vector (AdCN205) for co-expression of miRNA-34a and IL-24 in HCC cells.
- Assessed miRNA-34a and IL-24 expression levels post-infection.
- Evaluated the antitumor activity of the vector in vitro and in a xenograft mouse model of HCC.
- Measured the impact of miRNA-34a on its target genes, Bcl-2 and SIRT1.
Main Results:
- Reduced miRNA-34a expression was observed in HCC and correlated with poorer patient outcomes.
- The AdCN205 vector successfully co-expressed high levels of miRNA-34a and IL-24 in HCC cells.
- Co-expression of miRNA-34a and IL-24 via AdCN205 demonstrated significantly enhanced antitumor activity compared to single-gene vectors.
- miRNA-34a transfer inhibited the expression of its target genes, Bcl-2 and SIRT1.
- Treatment with AdCN205-IL-24-miR-34a resulted in complete regression of established HCC xenograft tumors in mice without recurrence.
Conclusions:
- Co-expression of miRNA-34a and IL-24 using an oncolytic adenovirus is a potent strategy for HCC therapy.
- This dual-targeting approach overcomes limitations of single-agent therapies.
- The developed adenoviral vector shows promise for effective, simultaneous delivery of tumor suppressor genes and miRNAs in cancer treatment.
